Can the whole 4X or 8X panel be run on a single vial?
Not as an execution promise. Controlled Rapid-only accession reserves one sealed analytical container, but the laboratory may request supplemental material until a signed ledger proves every destructive preparation fits and the molecular platform is qualified. A "10 mg" active label is not proof of total usable cake. A conservative USP <71> submitted-container accession uses two dedicated culture containers, one for FTM and one for SCDM, plus one reserved analytical/Rapid container, for three total. USP <71> may be ordered and accessioned; unresolved procedure, exact product/matrix suitability, or media-control findings are surfaced to our staff for resolution and do not block entry, signing, or release. Optional consistency vials answer a separate question about vial-to-vial consistency.
What is the minimum sample amount for 4X, 8X, a retest, or consistency testing?
There is no safe universal mg or mL minimum. For controlled intake, ordinary 4X/8X work initially reserves one sealed analytical container, but the label claim does not prove total usable material and the lab may request more after reviewing the exact panel, matrix, presentation, destructive preparations, controls, repeats, and reserve. A submitted-container USP <71> plan conservatively uses two dedicated culture containers plus the analytical container. Consistency testing requires at least two independently analyzed same-lot vials. A retest is reviewed against remaining retained material and the new scope; never promise that the original vial or reserve is sufficient.
Does the sterility test need more than one vial?
Yes. The conservative USP <71> submitted-container accession uses both Fluid Thioglycollate Medium (FTM) and Soybean-Casein Digest Medium (SCDM), with one dedicated whole sealed container for each medium, plus one reserved analytical/Rapid container, for three total. A "10 mg" active label does not establish total physical fill, and the laboratory may request supplemental material until the exact analytical ledger is qualified. Required culture containers are included with the service and are not paid conformity repeats. A one-container Rapid DNA result remains a research screen, not a sterility test or viable-CFU claim.
Is a one-vial sterility result a lot-release pass under USP 71?
No, and we will not certify it as one. A one-container Rapid DNA result is not USP <71> at all. For a USP <71> production-batch claim, the chapter's parenteral sampling table applies per medium: for a lot up to 100 finished containers, at least 10% or 4 containers, whichever is greater, are tested in each medium. A 40-container lot therefore has a conservative minimum of eight culture containers: four for FTM and four for SCDM, plus the separately reserved analytical allocation. Axiom accepts the declared service into controlled accession. An incomplete laboratory qualification or material ledger prevents a batch-representative PASS and is surfaced to our staff for resolution; entry, signing, and release are not blocked. Required culture containers are not paid conformity repeats.
Is conformity testing the same thing as cross-vial consistency?
Yes: one product, two names, and the naming is our fault. "Per-vial conformity" is the choice you make on a multi-vial submission (each vial is analysed separately instead of pooled); "cross-vial consistency" is what those extra vials are billed as, starting at $95 and stepping down per vial. The mechanics: send at least two vials from one lot in a single submission; each vial's identity mass, purity, and net content are recorded independently. Every vial must meet its own acceptance criterion, the content mean must be on target, and the content coefficient of variation must sit inside the 5% default limit (tightenable per lot). Two vials is the minimum because a single vial has no uniformity to measure.
What does "Containers tested" on the certificate mean?
For a USP <71> execution, it is the observed number of physical containers allocated to the two-media sterility determination, locked from the accepted service plan and verified against vial intake before release. It is not automatically the shipment's total physical-vial count and does not include analytical containers established by the signed panel material budget or optional consistency vials. The count prints face up so a no-growth result cannot be read as covering containers that were never tested. The Rapid DNA research screen does not use a USP <71> containers-tested claim.